Distinguished Investigators

Groups

Alzheimer's disease is the sixth leading cause of death in the United States, impacting an estimated 5.3 million Americans. Despite widespread research into treatments for Alzheimer's disease, there is a staggering 99.6% failure rate in clinical trials to bring new treatments to market.

Allen Distinguished Investigator (ADI) grants were given to five teams of researchers with projects that will open new and innovative avenues of research in Alzheimer's disease by uncovering its elusive biological roots. The projects are funded at a total of $7 million over three years.

Fred "Rusty" Gage, Ph.D.

Salk Institute for Biological Studies

Jeffrey Iliff, Ph.D.

Oregon Health & Science University

Martin Kampmann, Ph.D.

University of California, San Francisco

Aimee Kao, Ph.D.

University of California, San Francisco

Ragnhildur Thóra Káradóttir, Ph.D.

University of Cambridge

Michael Keiser, Ph.D.

University of California, San Francisco

David Kokel, Ph.D.

University of California, San Francisco

William Rooney, Ph.D.

Oregon Health & Science University

Alzheimer’s Disease (2015)

Dysregulation of pH dynamics in Alzheimer Disease Pathogenesis

Alzheimer’s Disease (2015)

Human age-equivalent directly induced neurons to study functional phenotypes of Alzheimer’s disease.

Alzheimer’s Disease (2015)

Mapping glymphatic pathway function in the human brain: Detecting glio-vascular changes that slow amyloid β clearance from the aging brain

Alzheimer’s Disease (2015)

Resolving white matter dysfunction in Alzheimer's disease with novel biosensors

Alzheimer’s Disease (2015)

Systematic elucidation of cellular networks controlling proteinopathy in Alzheimer’s disease